The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study.

ABSTRACT: Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial for routine diagnostics. Till date these data have been derived mostly from clinical trials, and thus collected in pre-selected populations. We therefore screened 'allcomers' with a newly diagnosed non-small cell lung carcinoma (NSCLC) for the frequencies of these mutations. A cohort study. Lung cancer centre in a tertiary care hospital. Within 15 months, a total of 552 cases with NSCLC were eligible for analysis. Frequency of scrutinising exons 18, 19 and 21 for the presence of activating EGFR mutation and secondary codon 12 and 13 for activating KRAS mutations. Of the 552 patients, 27 (4.9%) showed a mutation of EGFR. 19 of these

SUBMITTER: Boch C 

PROVIDER: S-EPMC3641502 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature